Table 1.
Baseline patient characteristics
| Characteristic | All evaluable patients (n = 34) |
| Age (y) | |
| Median | 72.3 |
| Range | 56.6–88.7 |
| Total Gleason score, n (%) | |
| 6 | 2 (5.9) |
| 7 | 13 (38.2) |
| 8 | 3 (8.8) |
| 9 | 10 (29.4) |
| Unavailable | 6 (17.6) |
| Metastatic sites at time of biopsy, n (%) | |
| Bone | 25 (73.5) |
| Lung | 2 (5.9) |
| Liver | 0 (0.0) |
| Visceral (other than lung and liver)* | 1 (2.9) |
| Lymph nodes | 6 (17.6) |
| ECOG performance status score, n (%) | |
| 0 | 20 (58.8) |
| 1 | 14 (41.2) |
| 2–4 | 0 (0.0) |
| PSA | |
| Median | 36.6 |
| Range | 2.3–2,137.3 |
Patient demographics for evaluable patients. Demographic information for the 34 evaluable patients is shown. ECOG, Eastern Cooperative Oncology Group.
*
Ischioanal fossa mass.